Clinical Trial Detail

NCT ID NCT04364620
Title AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alethia Biotherapeutics
Indications

lung non-small cell carcinoma

Therapies

AB-16B5 + Docetaxel

Age Groups: senior adult

No variant requirements are available.